MedTrace Logo

Fiber Tolerability in Children

NCT02519374 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-02-05

No results posted yet for this study

Summary

Assessment of the digestive tolerability of the PROMITOR® .

Conditions

  • Signs and Symptoms, Digestive

Interventions

DRUG

Placebo (including Maltodextrin)

DRUG

PROMITOR® (including Maltodextrin)

Investigational product dose 1

DRUG

PROMITOR® (including Maltodextrin)

Investigational product dose 2

DRUG

PROMITOR® (including Maltodextrin)

Investigational product dose 3

Sponsors & Collaborators

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02519374 on ClinicalTrials.gov